EMAIL THIS PAGE TO A FRIEND

Antimicrobial agents and chemotherapy

In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.


PMID 26149995

Abstract

There are currently 18 drug classes for the treatment of tuberculosis, including those in the development pipeline. An in silico simulation enabled combing the innumerably large search space to derive multidrug combinations. Through the use of ordinary differential equations (ODE), we constructed an in silico kinetic platform in which the major metabolic pathways in Mycobacterium tuberculosis and the mechanisms of the antituberculosis drugs were integrated into a virtual proteome. The optimized model was used to evaluate 816 triplets from the set of 18 drugs. The experimentally derived cumulative fractional inhibitory concentration (∑FIC) value was within twofold of the model prediction. Bacterial enumeration revealed that a significant number of combinations that were synergistic for growth inhibition were also synergistic for bactericidal effect. The in silico-based screen provided new starting points for testing in a mouse model of tuberculosis, in which two novel triplets and five novel quartets were significantly superior to the reference drug triplet of isoniazid, rifampin, and ethambutol (HRE) or the quartet of HRE plus pyrazinamide (HREZ).

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A3650
Amikacin hydrate, aminoglycoside antibiotic
C22H43N5O13 · xH2O
E4630
Ethambutol dihydrochloride, antimycobacterial
C10H24N2O2 · 2HCl
T6330
THI
C9H14N2O5